Longevity-focused gene therapy company Rejuvenate Bio has received a grant of USD 4 million from the California Institute for Regenerative Medicine (CIRM).
The funding will be used to speed up the development of the company's gene therapy candidate, RJB-0402; specifically, its IND-enabling activities. The intention is to move this therapy into clinical trials for patients suffering from desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM).
Rejuvenate Bio specializes in developing gene therapies to combat chronic age-related diseases. Founded as a spinoff from the Wyss Institute at Harvard, the company uses advanced gene therapy techniques to address conditions such as heart disease, kidney failure, Type II diabetes, and obesity. Its key candidates include RJB-01, aimed at treating mitral valve disease in dogs, and gene therapies targeting multiple age-related ailments by modulating specific genes associated with longevity.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.